Shattuck Labs Set to Showcase Innovations at Healthcare Conference

Author: Henry Turner Updated: 04-02-2025 05:18 PM

Shattuck Labs to Present at the Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC — Shattuck Labs, Inc. (NASDAQ: STTK), a leader in biotechnology, is excited to announce its participation in the 24th Annual Needham Virtual Healthcare Conference. The event is set to take place from April 7 to April 10, and Shattuck Labs will host presentations and one-on-one meetings during this important industry gathering.

Event Details and Presentation Schedule

During the conference, Shattuck's Chief Executive Officer, Dr. Taylor Schreiber, will deliver a presentation on April 9 at 3:00 PM EDT. This will provide an excellent opportunity for attendees to gain insights into the company's innovative work in developing novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors.

Accessing the Conference

For those unable to attend live, a live webcast will be available on Shattuck’s official website in the Events and Presentations section. A replay of the presentation will also be archived for one month following the event, making it convenient for interested parties to catch up on the latest developments.

Insights into Shattuck's Lead Program: SL-325

One of the key focuses of Shattuck Labs is SL-325, a promising candidate that acts as a blocking antibody for Death Receptor 3 (DR3). This innovative therapy aims for a complete blockade of the DR3/TL1A pathway, which has been clinically validated. Preclinical studies suggest that SL-325 exhibits high affinity binding and offers enhanced activity compared to existing TL1A antibodies.

Advancement and Development Timeline

Recently, SL-325 completed a Good Laboratory Practice (GLP) toxicology study in non-human primates. Shattuck Labs anticipates filing an Investigational New Drug (IND) application in the third quarter of 2025, marking a significant step forward in its development timeline.

About Shattuck Labs, Inc.

Founded with a mission to address inflammatory and immune-mediated diseases, Shattuck Labs, Inc. (NASDAQ: STTK) is at the forefront of biotechnology, specializing in groundbreaking treatments. The company’s expertise in protein engineering fuels its development of SL-325, aiming to provide more effective solutions for patients suffering from inflammatory bowel disease (IBD) and related conditions.

Company Presence and Future Directions

Shattuck Labs operates from both Austin, Texas, and Durham, North Carolina, while continuously exploring future opportunities to expand its innovative pipeline. As the company focuses on driving the clinical translation of its research, it remains committed to enhancing patient care and treatment options.

Frequently Asked Questions

What does Shattuck Labs do?

Shattuck Labs focuses on developing novel therapeutics targeting immune-related diseases, particularly through its lead program SL-325.

When will SL-325 be available for clinical use?

The IND filing for SL-325 is expected in the third quarter of 2025, moving it closer to clinical trials.

Who will present at the Needham Virtual Healthcare Conference?

Dr. Taylor Schreiber, the Chief Executive Officer of Shattuck Labs, will be presenting.

Where can I watch the conference live?

A live webcast will be available on Shattuck’s official website during the conference.

What is the significance of the DR3/TL1A pathway?

The DR3/TL1A pathway plays a pivotal role in inflammatory responses, making it a critical target for therapeutic exploration.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.